TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36108594

Group type: EXPERIMENTAL
Intervention: IST + c-Ecu
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Ecu + c-IST
Number of subjects: 181

Group type: COMPARATOR
Intervention: IST alone
Number of subjects: 181
Study: 36108661

Group type: EXPERIMENTAL
Intervention: Selpercatinib (160 mg twice daily)
Number of subjects: 45
Study: 36109029

Group type: EXPERIMENTAL
Intervention: Digital exposure treatment
Number of subjects: 0
Study: 36109108

Group type: EXPERIMENTAL
Intervention: Cumulative systolic blood pressure (SBP) load
Number of subjects: 9338
Study: 36109358

Group type: EXPERIMENTAL
Intervention: rRetrorectus
Number of subjects: 59

Group type: COMPARATOR
Intervention: IPOM
Number of subjects: 59
Study: 36109430

Group type: EXPERIMENTAL
Intervention: Immediate drug withdrawal after delivery
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Delayed drug withdrawal at 6 weeks after delivery
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control group (untreated subjects)
Number of subjects: 264
Study: 36109652

Group type: EXPERIMENTAL
Intervention: Microencapsulated watermelon rind (MWR) 30 g containing 4 g of L-citrulline
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 36109693

Group type: EXPERIMENTAL
Intervention: Frailty Phenotype (FP)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Frailty Index (FI)
Number of subjects: 44
Study: 36110103

Group type: EXPERIMENTAL
Intervention: Women's FBO membership
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women's FBO participation
Number of subjects: 0
Study: 36110277

Group type: EXPERIMENTAL
Intervention: Integrative medicine (acupuncture, Chinese herbs, repeated transcranial magnetic stimulation)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Standard care (basic treatment, general nursing care, exercise therapy)
Number of subjects: 202
Study: 36110295

Group type: EXPERIMENTAL
Intervention: Intermittent PEG-IFNα therapy
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Initial treatment HBsAg response
Number of subjects: 304
Study: 36110925

Group type: EXPERIMENTAL
Intervention: Atraumatic spinal needle with a 27 gauge tip and a 22 gauge shaft
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Research LP procedures
Number of subjects: 326
Study: 36110934

Group type: EXPERIMENTAL
Intervention: trabectedin + olaparib
Number of subjects: 0
Study: 36110959

Group type: EXPERIMENTAL
Intervention: E150 (150 mg erlotinib for non-smokers)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: E300 (300 mg erlotinib for smokers)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Early in-treatment [18]FDG PET/CT
Number of subjects: 19
Study: 36111056

Group type: EXPERIMENTAL
Intervention: Right thoracic approach (RTA)
Number of subjects: 861

Group type: COMPARATOR
Intervention: Left thoracic approach (LTA)
Number of subjects: 861
Study: 36111149

Group type: EXPERIMENTAL
Intervention: Ozone treatment
Number of subjects: 0
Study: 36111288

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP) long-acting injectable
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral antipsychotic (OAP) treatment
Number of subjects: 0
Study: 36111611

Group type: EXPERIMENTAL
Intervention: Brief video intervention (five versions differing by protagonist gender and race/ethnicity)
Number of subjects: 0
Study: 36111801

Group type: EXPERIMENTAL
Intervention: FFR (Fractional Flow Reserve)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: iFR (instantaneous wave-free ratio)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: IVUS (Intravascular Ultrasound)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Deferral of revascularization based on iFR
Number of subjects: 300
Study: 36111839

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy initiated with a delay (≥8 weeks after surgical resection)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: No adjuvant therapy
Number of subjects: 101

Group type: COMPARATOR
Intervention: Timely initiation of adjuvant chemotherapy
Number of subjects: 101
Study: 36111952

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus bevacizumab (atezo-beva)
Number of subjects: 1244

Group type: COMPARATOR
Intervention: Nivolumab
Number of subjects: 1244
Study: 36111991

Group type: EXPERIMENTAL
Intervention: BUP-XR (Buprenorphine Extended Release)
Number of subjects: 533
Study: 36112034

Group type: EXPERIMENTAL
Intervention: Conventional testicular sperm extraction (c-TESE)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Young cohort (15-22 years old)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Adult cohort (23-43 years old)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Upper quartile of AMH plasma levels
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Lower quartile of AMH plasma levels
Number of subjects: 119
Study: 36112116

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0
Study: 36112183

Group type: EXPERIMENTAL
Intervention: Drinking Olive Leaf Tea
Number of subjects: 0
Study: 36112399

Group type: EXPERIMENTAL
Intervention: mRNA-1273.214
Number of subjects: 814

Group type: COMPARATOR
Intervention: mRNA-1273
Number of subjects: 814
Study: 36112541

Group type: EXPERIMENTAL
Intervention: Mobocertinib (Exkivity)
Number of subjects: 114
Study: 36112577

Group type: EXPERIMENTAL
Intervention: ICU group
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Patients not admitted to the ICU
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Patients who had not required mechanical ventilation
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 178
Study: 36113242

Group type: EXPERIMENTAL
Intervention: FCN-159 (12 mg QD)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: FCN-159 (≥6 mg QD)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: FCN-159
Number of subjects: 33
Study: 36113405

Group type: EXPERIMENTAL
Intervention: Family involvement in decision making
Number of subjects: 281

Group type: COMPARATOR
Intervention: No family involvement
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Family involvement
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Patient-led or physician-led decision making
Number of subjects: 281

Group type: COMPARATOR
Intervention: Family-led or family-alone decision making
Number of subjects: 281
Study: 36113895

Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (T-VEC) followed by intratumoral injection of CD1c (BDCA-1)
Number of subjects: 13
Study: 36113946

Group type: EXPERIMENTAL
Intervention: Relational harm reduction approaches
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Structural harm reduction strategies (e.g., syringe service programmes)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Patient Assessment of Provider Harm Reduction Scale (25-item scale)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Human-centred design approaches
Number of subjects: 500
Study: 36113962

Group type: EXPERIMENTAL
Intervention: Mycophenolic acid (MPA) treatment
Number of subjects: 1977

Group type: COMPARATOR
Intervention: Not treated with MPA (Control)
Number of subjects: 1977

Group type: EXPERIMENTAL
Intervention: MPA treatment (adjusted analysis)
Number of subjects: 1977
Study: 36114102

Group type: EXPERIMENTAL
Intervention: dupilumab 300 mg every 2 weeks up to 96 weeks
Number of subjects: 2282
Study: 36114184

Group type: EXPERIMENTAL
Intervention: Aerobic fitness levels
Number of subjects: 53
Study: 36114405

Group type: EXPERIMENTAL
Intervention: Cycloplegic biometry (cLP)
Number of subjects: 821

Group type: COMPARATOR
Intervention: Non-cycloplegic biometry (nLP)
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: ΔLP
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: |ΔLP|
Number of subjects: 821
Study: 36114455

Group type: EXPERIMENTAL
Intervention: Preoperative AChE activity (U/gHb)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Postoperative AChE activity (U/gHb)
Number of subjects: 127
Study: 36114495

Group type: EXPERIMENTAL
Intervention: Higher TyG index group
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: TyG index increase
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: TyG index
Number of subjects: 935
Study: 36114723

Group type: COMPARATOR
Intervention: Aerobic exercise capacity (3-min step test)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Cough strength (peak expiratory flow meter)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Thoracoabdominal mobility (upper chest, lower chest, and abdomen)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Posture (Corbin postural assessment scale)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Depression (Children's Depression Inventory)
Number of subjects: 27
Study: 36114762

Group type: EXPERIMENTAL
Intervention: IBS-C subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IBS-D subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IBS-C/CH4+
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IBS-D
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IBS-C/CH4+ subjects
Number of subjects: 0
Study: 36115002

Group type: EXPERIMENTAL
Intervention: Spline-based models
Number of subjects: 0

Group type: COMPARATOR
Intervention: Linear mixed model
Number of subjects: 0
Study: 36115665

Group type: EXPERIMENTAL
Intervention: Short-term exposure to atmospheric pollution (MobiFem project)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregnancy lifestyle (EnviFem project)
Number of subjects: 0
Study: 36115673

Group type: EXPERIMENTAL
Intervention: Neoadjuvant SBRT (8 Gy × 3 fractions) plus PD-1 inhibitor (tislelizumab) administered in two cycles with a 3-week interval before surgery.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adjuvant tislelizumab for 1 year after surgery.
Number of subjects: 20
Study: 36115674

Group type: EXPERIMENTAL
Intervention: REVEAL(OT) intervention added to standard multidisciplinary chronic pain treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: REVEAL(OT) intervention
Number of subjects: 40
Study: 36115679

Group type: EXPERIMENTAL
Intervention: Healthy pregnant women (Cohort A)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Pregnant women with suspected sepsis (Cohort B)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Pilot study (30 pregnant women undergoing elective caesarean section)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Routine biochemical tests (C reactive protein, lactate, white blood cell count)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Transcriptomic, lipidomic, and metabolomic analyses
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Qualitative and functional immunophenotyping
Number of subjects: 230
Study: 36115714

Group type: EXPERIMENTAL
Intervention: Operative pulmonary artery wave reflection
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Pulmonary artery blood flow distribution
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Right ventricular ejection fraction
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Right ventricular ejection fraction and right ventricular strain
Number of subjects: 27
Study: 36115931

Group type: EXPERIMENTAL
Intervention: Anti-PD-1 combination therapy
Number of subjects: 0
Study: 36115947

Group type: EXPERIMENTAL
Intervention: erenumab 70-140 mg s.c. every 28 days for one year
Number of subjects: 77
Study: 36115980

Group type: EXPERIMENTAL
Intervention: Simvastatin, L-arginine, and tetrahydrobiopterin
Number of subjects: 10
Study: 36116169

Group type: EXPERIMENTAL
Intervention: Anlotinib combined with platinum-etoposide (chemotherapy)
Number of subjects: 86
Study: 36116288

Group type: EXPERIMENTAL
Intervention: Passive leg raising (PLR)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Norepinephrine administration during PLR
Number of subjects: 33
Study: 36116293

Group type: EXPERIMENTAL
Intervention: remedē System Therapy (transvenous phrenic nerve stimulation)
Number of subjects: 500
Study: 36116359

Group type: EXPERIMENTAL
Intervention: CARMELINA (n = 2666)
Number of subjects: 6962

Group type: EXPERIMENTAL
Intervention: CAROLINA (n = 4296)
Number of subjects: 6962

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 6962
Study: 36116420

Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg intravenously
Number of subjects: 151
Study: 36116506

Group type: EXPERIMENTAL
Intervention: Anti-CEL IgG and IgA antibodies in patients with HS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-CEL IgG (IgG2 subclass)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CEL and anti-CEL producing plasmablasts
Number of subjects: 0
Study: 36116543

Group type: EXPERIMENTAL
Intervention: Custom-made decompression appliance fabricated using a digital workflow
Number of subjects: 6
Study: 36116752

Group type: EXPERIMENTAL
Intervention: Acute hepatitis B virus (aHBV) infection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chronic hepatitis B virus (cHBV) untreated controls
Number of subjects: 60
Study: 36116866

Group type: EXPERIMENTAL
Intervention: Enteral feeding
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Post-pyloric feeding tube location
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Abundant microaspiration (positive pepsin A ≥ 6.25 ng/mL)
Number of subjects: 283

Group type: COMPARATOR
Intervention: No enteral feeding
Number of subjects: 283
Study: 36117003

Group type: EXPERIMENTAL
Intervention: mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273)
Number of subjects: 8000

Group type: EXPERIMENTAL
Intervention: mRNA COVID-19 vaccines
Number of subjects: 8000

Group type: COMPARATOR
Intervention: mRNA-1273
Number of subjects: 8000
Study: 36117166

Group type: EXPERIMENTAL
Intervention: Post-direct-acting antiviral agent HCC
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Tumor-infiltrating lymphocytes
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: HCC variants
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Old age, male gender, elevated alpha-fetoprotein level, tumor size, and background liver
Number of subjects: 530
Study: 36117179

Group type: EXPERIMENTAL
Intervention: Regadenoson stress myocardial contrast echocardiography (MCE)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Septal myectomy (in 3 patients)
Number of subjects: 32
Study: 36117330

Group type: EXPERIMENTAL
Intervention: Low testosterone (LT) group
Number of subjects: 68

Group type: COMPARATOR
Intervention: Normal testosterone (NT) group
Number of subjects: 68
Study: 36117519

Group type: EXPERIMENTAL
Intervention: Liver elastography
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Spleen elastography
Number of subjects: 31

Group type: COMPARATOR
Intervention: Changes in HVPG results
Number of subjects: 31
Study: 36117973

Group type: EXPERIMENTAL
Intervention: Low-dose dexmedetomidine (0.1 to 0.2 μg/kg/h)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 36118431

Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP) plus standard intervention
Number of subjects: 42

Group type: COMPARATOR
Intervention: Waiting list control (standard care)
Number of subjects: 42
Study: 36118751

Group type: EXPERIMENTAL
Intervention: Sugar-sweetened soda (1 L/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Semi-skimmed milk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspartame-sweetened soda
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study: 36119522

Group type: EXPERIMENTAL
Intervention: mDCF (docetaxel 40 mg/m², cisplatin, and 5-fluorouracil) followed by chemoradiotherapy
Number of subjects: 0
Study: 36119552

Group type: EXPERIMENTAL
Intervention: Multimodal circuit exercise
Number of subjects: 164

Group type: COMPARATOR
Intervention: Cycle of multidisciplinary lectures on pain and stretching exercise
Number of subjects: 164
Study: 36119641

Group type: EXPERIMENTAL
Intervention: cCRT (concurrent chemoradiotherapy)
Number of subjects: 3151

Group type: EXPERIMENTAL
Intervention: EGFR-TKI monotherapy
Number of subjects: 3151
Study: 36119669

Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin A (BoNT-A) treatment
Number of subjects: 30
Study: 36119746

Group type: EXPERIMENTAL
Intervention: Machine learned algorithm
Number of subjects: 230
Study: 36119770

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 36119787

Group type: EXPERIMENTAL
Intervention: Sofosbuvir combined with ledipasvir (SOF/LDV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simeprevir with pegylated interferon plus ribavirin (Sim+IFN)
Number of subjects: 0
Study: 36120090

Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA vaccine (30 μg), administered in two doses intramuscularly, 21 days apart
Number of subjects: 959

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 959
Study: 36120713

Group type: EXPERIMENTAL
Intervention: Personalized digital intervention based on social rhythm regulation principles
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (standard outpatient treatment)
Number of subjects: 133
Study: 36120850

Group type: EXPERIMENTAL
Intervention: Salvage radiation therapy (sRT) with or without 2 years of Bicalutamide
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Early sBCR
Number of subjects: 421

Group type: COMPARATOR
Intervention: Late sBCR
Number of subjects: 421
Study: 36121014

Group type: EXPERIMENTAL
Intervention: Provisional stenting
Number of subjects: 430
Study: 36121244

Group type: EXPERIMENTAL
Intervention: Pharmacomechanical catheter-directed thrombolysis (PM-CDT) using the Bashir endovascular catheter with 7 mg tPA infused over 5 hours.
Number of subjects: 109
Study: 36121499

Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin (EC-ASA)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Plain aspirin (P-ASA)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both EC-ASA and P-ASA
Number of subjects: 42
Study: 36121707

Group type: EXPERIMENTAL
Intervention: ARP strategy (LSM < 1.805 m/s or SSM < 2.445 m/s and PLT > 110 × 10^9/L)
Number of subjects: 741

Group type: COMPARATOR
Intervention: Baveno VI criteria
Number of subjects: 741
Study: 36121803

Group type: EXPERIMENTAL
Intervention: Fitbit Charge 3 activity tracker
Number of subjects: 27
Study: 36122315

Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 796
Study: 36122888

Group type: EXPERIMENTAL
Intervention: Culprit drug identification through combined skin testing, in vitro testing, or drug provocation tests.
Number of subjects: 357
Study: 36122968

Group type: EXPERIMENTAL
Intervention: FaCES intervention
Number of subjects: 1226

Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 1226
Study: 36123064

Group type: EXPERIMENTAL
Intervention: Decision Aid for Lung Cancer Molecular Testing (DA_LCMT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Structured interviews with qualitative research methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Descriptive statistics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative data analysis using grounded theory
Number of subjects: 0
Study: 36123069

Group type: EXPERIMENTAL
Intervention: Rapid serological test targeting IgM and IgG against the receptor binding domain of SARS-CoV-2
Number of subjects: 3648

Group type: COMPARATOR
Intervention: Not vaccinated participants
Number of subjects: 3648

Group type: EXPERIMENTAL
Intervention: Booster vaccination
Number of subjects: 3648
Study: 36123070

Group type: EXPERIMENTAL
Intervention: Asthma confirmed through diagnostic tests (spirometry, fraction of exhaled nitric oxide, blood eosinophil count) and patient-reported outcome measures.
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: Further evaluation of patients with asthma, difficult-to-treat asthma, and severe asthma after 3 months.
Number of subjects: 15000
Study: 36123081

Group type: EXPERIMENTAL
Intervention: Proactive and brief electronic multiple behaviour change intervention with individualised and motivation-enhancing computer-generated feedback at months 0, 1, and 3.
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Proactive and brief electronic multiple behaviour change intervention.
Number of subjects: 175
Study: 36123124

Group type: EXPERIMENTAL
Intervention: Low PSV and carotid plaques (CPs)
Number of subjects: 2623
Study: 36123169

Group type: EXPERIMENTAL
Intervention: Opioid vaccines
Number of subjects: 0

Group type: COMPARATOR
Intervention: COVID-19 vaccines
Number of subjects: 0
Study: 36123234

Group type: EXPERIMENTAL
Intervention: CRISPR-Cas9-based genome editing
Number of subjects: 0
Study: 36123540

Group type: EXPERIMENTAL
Intervention: Full peritoneal penetration with tumor cells on the peritoneal surface (n=89)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: 0-99 µm distance to the peritoneal surface (n=34)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: 100-999 µm distance to the peritoneal surface (n=33)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: ≥1000 µm distance to the peritoneal surface (n=33)
Number of subjects: 189
Study: 36123697

Group type: EXPERIMENTAL
Intervention: TransCon TLR7/8 Agonist
Number of subjects: 0
Study: 36123761

Group type: EXPERIMENTAL
Intervention: SMART portal (digital therapeutic self-management tool)
Number of subjects: 22
Study: 36123771

Group type: EXPERIMENTAL
Intervention: Hospitalized children (137 participants)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Community children (84 participants)
Number of subjects: 137
Study: 36124180

Group type: EXPERIMENTAL
Intervention: HLX04-O intravitreal injections at a dose of 1.25 mg/0.05 mL every four weeks
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: HLX04-O intravitreal injections
Number of subjects: 1
Study: 36124294

Group type: EXPERIMENTAL
Intervention: Rosuvastatin/Ezetimibe (Trezete®)
Number of subjects: 103
Study: 36124629

Group type: EXPERIMENTAL
Intervention: Bimiralisib
Number of subjects: 8
Study: 36124645

Group type: EXPERIMENTAL
Intervention: Lacto-vegetarian diet
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: Ovolacto-vegetarian diet
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: Pescovegetarian diet
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: Low-meat diet
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: Medium-meat diet
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: High-meat diet
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: Vegetarian diets
Number of subjects: 30000
Study: 36124692

Group type: EXPERIMENTAL
Intervention: Women with angina (n = 931)
Number of subjects: 1770

Group type: COMPARATOR
Intervention: Women with angina (n = 931) and Women with unspecific chest pain (n = 839)
Number of subjects: 1770
Study: 36124767

Group type: EXPERIMENTAL
Intervention: Edge-to-Edge Transcatheter Mitral Valve Repair
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal Medical Treatment
Number of subjects: 0